{"nctId":"NCT01863680","briefTitle":"Phase 3 Trial to Evaluate the Efficacy and Safety of COL-1620 Vaginal Progesterone Gel","startDateStruct":{"date":"2013-07"},"conditions":["Luteal Hormone Supplementation in In-vitro Fertilization","Embryo Transfer"],"count":178,"armGroups":[{"label":"COL-1620","type":"EXPERIMENTAL","interventionNames":["Drug: COL-1620","Drug: Gonadotropin-releasing hormone (GnRH) analogue","Drug: Follicle-stimulating hormone (FSH)","Drug: Human Chorionic Gonadotropin (hCG)"]}],"interventions":[{"name":"COL-1620","otherNames":[]},{"name":"Gonadotropin-releasing hormone (GnRH) analogue","otherNames":[]},{"name":"Follicle-stimulating hormone (FSH)","otherNames":[]},{"name":"Human Chorionic Gonadotropin (hCG)","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Japanese race\n* Woman with a history of infertility and in whom In-vitro fertilization and embryo transfer (IVF/ET) is indicated\n* The controlled ovarian stimulation (COS) therapy is gonadotropin-releasing hormone (GnRH) analogue (agonist or antagonist) in combination with a follicle-stimulating hormone (FSH) containing preparation\n* Healthy premenopausal woman aged between 20 and 45 years (inclusive) and wishing to conceive\n* Body mass index (BMI) of 17.0 to 25.0 kilogram per square meter (kg/m\\^2) (inclusive)\n* A negative pregnancy test (urinary beta-human chorionic gonadotropin \\[hCG\\]) prior to starting COS\n* Normal cervical smear result (Papanicolaou \\[PAP\\] test: Negative for Intraepithelial Lesion or Malignancy \\[NILM\\] or \\[Atypical Squamous Cells of Undetermined Significance {ASC-US} and Human Papillomavirus {HPV} negative\\]) within 12 months prior to the date of informed consent. If not available, a cervical smear and HPV test will be performed as part of Screening\n* No clinically significant abnormal findings in the screening hematology, biochemistry and urinalysis parameters\n* Full comprehension of the study and voluntary written informed consent obtained in writing prior to any trial-related activities\n\nExclusion Criteria:\n\n* History of recurrent pregnancy loss (defined as 3 or more previous spontaneous abortions)\n* History of 3 or more consecutive cancelled or failed (no clinical pregnancy) IVF/ET cycles\n* Abnormal hemorrhage of the reproductive tract of undetermined origin\n* Any contraindication to being pregnant and/or carrying a pregnancy to term (for example, malformations of sexual organs or fibroid tumors of the uterus incompatible with pregnancy)\n* Uterine myoma requiring treatment\n* Extra-uterine pregnancy within the last 3 months prior to the date of informed consent\n* History or presence of intracranial tumor (for example, hypothalamic or pituitary tumor)\n* Presence of or suspected gonadotropin- or estrogen-dependent malignancy (for example, ovarian, uterine or mammary carcinoma)\n* Ovarian enlargement or cyst of unknown etiology\n* Breast-feeding or lactation\n* History of severe Ovarian Hyperstimulation Syndrome (OHSS) (Classification of OHSS Severity, as per Japan Reproductive/Endocrine Working Group)\n* Known Human Immunodeficiency Virus (HIV)-positive status, or a history of or current active infection with Hepatitis B or C\n* Known allergy or hypersensitivity to progesterone preparations or gonadotropin preparations and/or their excipients, or any contraindication to receive medication for controlled ovarian stimulation (for example, gonadotropin, GnRH analogues, combined oral contraceptive pill, as appropriate)\n* History of or suspected alcohol or substance abuse within 5 years prior to the date of informed consent\n* Clinically significant systemic disease (for example, insulin-dependent diabetes, epilepsy, severe migraine, acute porphyria, hepatic, renal or cardiovascular disease, severe corticosteroid-dependent asthma)\n* Active thrombophlebitis, thromboembolic disorder or cerebral apoplexy, or a history of such conditions\n* Other significant disease that in the Investigator's or Sub-Investigator's opinion would exclude the subject from the trial\n* Participation in another clinical trial within 3 months prior to the date of informed consent or simultaneous participation in another clinical trial\n* Legal incapacity or limited legal capacity","healthyVolunteers":false,"sex":"FEMALE","minimumAge":"20 Years","maximumAge":"45 Years","stdAges":["ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Clinical Pregnancy Rate Per Embryo Transfer","description":"Clinical pregnancy was defined as the presence of a fetal sac on transvaginal ultrasound (TVUS) during Week 5 or the presence of an extra-uterine pregnancy (as confirmed during surgery or by 2 positive serum beta-human chorionic gonadotropin (beta-hCG) results from Week 5). The clinical pregnancy rate was calculated as number of subjects who were clinically pregnant divided by the number of subjects who had at least 1 embryo transferred.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"28.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Biochemical Pregnancy Rate Per Embryo Transfer","description":"Biochemical pregnancy was defined as any miscarriage without any evidence of a fetal sac on TVUS during Visit 6 (Week 5), but with a positive serum beta-hCG pregnancy test result at Visit 5 (Day 14+/-3). Biochemical pregnancy rate was calculated as the number of subjects who had no fetal sac observed during Visit 6 (Week 5) TVUS assessment or subjects who had a positive serum pregnancy test at Visit 5 (Day 14+/-3) and no data recorded at Visit 6 (Week 5) divided by the number of subjects who has at least 1 embryo transferred.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Serum Progesterone Level","description":"Two pharmacokinetic (PK) samples were collected per subject for the measurement of serum progesterone concentrations; 1st sample at Visit 2-2 (prior to hCG administration) and second sample during Visit 5 (Day 14+/-3, 7 hours after the morning of investigational medicinal product administration).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.023","spread":"0.414"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"61.508","spread":"76.206"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.988","spread":"0.471"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.765","spread":"3.202"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":5,"n":149},"commonTop":["Ovarian hyperstimulation syndrome","Constipation","Abdominal pain","Diarrhoea","Hyperemesis gravidarum"]}}}